Close Menu

NEW YORK — The US Food and Drug Administration this week granted separate Emergency Use Authorizations for a CRISPR-based SARS-CoV-2 test developed by the University of California, San Francisco and Mammoth Biosciences, and two PCR-based tests from the Broad Institute and BioSewoom.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.